Hepion Pharma jumps as co to release mid-stage study results for NASH drug

Hepion Pharmaceuticals

22/05/2023 09:59

** Shares of drug developer Hepion Pharmaceuticals Inc 
 HEPA.O  surge ~52% to $13.45 premarket
    ** Co says it expects to release results from a mid-stage
trial before markets open on Monday for its experimental drug to
treat nonalcoholic steatohepatitis (NASH)
    ** NASH is a type of fatty liver disease which causes
inflammation and damage of liver and has no U.S. FDA-approved
therapies
    ** Separately, FDA advisers on Friday voted against
recommending approval of rival Intercept Pharmaceuticals'
 ICPT.O  NASH treatment 
    ** HEPA shares are up ~48% this year 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))